Last reviewed · How we verify
NGP 555
At a glance
| Generic name | NGP 555 |
|---|---|
| Also known as | NGP555 |
| Sponsor | NeuroGenetic Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose) (PHASE1)
- Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NGP 555 CI brief — competitive landscape report
- NGP 555 updates RSS · CI watch RSS
- NeuroGenetic Pharmaceuticals Inc portfolio CI